SCHEMBL20255476

SCHEMBL20255476

OCCCCc1ccc(I)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.41
LTA4H P09960 1/20 0.39
EPHX2 P34913 1/20 0.39
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
NFKB1 P19838 4/20 0.38
MAPT P10636 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
PKM P14618 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
THPO P40225 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20255474 0.94 LTA4H (0.43) CA2LTA4HEPHX2CYP4A11NFKB1
SCHEMBL20037897 0.86 CA2 (0.43) CA2CYP4F2CYP4A11NFKB1MAPT
SCHEMBL2089925 0.78 L3MBTL1 (0.35) NFKB1MAPTL3MBTL1KDM4EMEN1
SCHEMBL1749889 0.77
SCHEMBL18291548 0.77 SMN1; SMN2 (0.49) CA2CYP4F2CYP4A11NFKB1MAPT
SCHEMBL18291527 0.77 GABRP (0.50) CA2CYP4F2CYP4A11NFKB1MAPT
SCHEMBL1874065 0.77 CA2 (0.41) CA2LTA4HEPHX2CYP4F2CYP4A11
SCHEMBL20037801 0.77 SMN1; SMN2 (0.52) NFKB1MAPTL3MBTL1KDM4EMEN1
SCHEMBL20255199 0.77 KDM4E (0.41) NFKB1MAPTL3MBTL1KDM4EMEN1
SCHEMBL23583491 0.74 ESR1 (0.40) CA2CYP4F2CYP4A11NFKB1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 CA2 2465/4885LTA4H 3374/4885EPHX2 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.